Market Cap 35.70M
Revenue (ttm) 2.19M
Net Income (ttm) -24.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,104.57%
Debt to Equity Ratio 0.00
Volume 54,700
Avg Vol 191,220
Day's Range N/A - N/A
Shares Out 6.19M
Stochastic %K 19%
Beta 2.26
Analysts Strong Sell
Price Target $56.28

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a sm...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 466 6059
Address:
One Corporate Drive, 2nd Floor, South San Francisco, United States
ALGSmoon
ALGSmoon Jul. 15 at 5:58 PM
$ALGS I guess we see what it does at 5.50 trendnline.
1 · Reply
ALGSmoon
ALGSmoon Jul. 15 at 3:22 PM
$ALGS and just like that…the pumpers have left the building. The stock is giving back its gains, a new downtrend has begun and we’re right back to the same ole thing.
0 · Reply
biotrade123
biotrade123 Jul. 14 at 12:29 AM
$ALGS hmm.. why the AH big drop? ?
0 · Reply
ZRN227
ZRN227 Jul. 13 at 4:47 PM
$ALGS If anybody waiting for FDA approval they will wait long time. Chinese regulatory office is more efficient and faster. We might see the drug on their market even before the trials are done in USA. I believe the next customer will come from Asia also, but before that there will be a few insiders purchasing the stock at market price.
0 · Reply
JoButler
JoButler Jul. 13 at 3:00 PM
$ALGS just cleared an important development milestone. Enrollment is now complete for both Phase 2 B-SUPREME cohorts evaluating pevifoscorvir in chronic HBV, shifting the focus from recruitment to clinical readouts. The next major catalyst is topline safety and efficacy data expected in late Q3 2027. Until then, execution and data quality—not headlines—will likely drive the investment case.
2 · Reply
biotrade123
biotrade123 Jul. 13 at 2:41 PM
$ALGS pull back on low vol before it continues up??🤞🤞
0 · Reply
WillyT2
WillyT2 Jul. 11 at 4:06 PM
$ALGS Anyone who trades these low float tickers needs TapeGrid dot com, Profitable every week since using it. You can thank me later! $MIMI $ZBAO $JZXN
1 · Reply
Somedude632
Somedude632 Jul. 10 at 11:48 PM
0 · Reply
ZRN227
ZRN227 Jul. 10 at 8:03 PM
$ALGS This is an old news but so relevant for the future. There is still money left from the offering $26/share, and now they finally becoming profitable. https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-announces-105-million-private-placement
0 · Reply
Quantumup
Quantumup Jul. 10 at 6:14 PM
H.C. Wainwright (a/o 7/7) reit'd $ALGS Buy-$50 after hosting ALGS for a fireside chat. $GILD $ABUS ASMB GSK - IONS RHHBY VIR JNJ MDGL IVA VKTX LGND NVO Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2075644271281975530?s=20
0 · Reply
Latest News on ALGS
Aligos Therapeutics completes enrollment in B-SUPREME study

2026-07-13T12:06:13.000Z - 4 days ago

Aligos Therapeutics completes enrollment in B-SUPREME study


Aligos Therapeutics initiated with a Buy at Lake Street

2026-05-28T13:28:16.000Z - 7 weeks ago

Aligos Therapeutics initiated with a Buy at Lake Street


Aligos Therapeutics presents data at EASL congress

2026-05-27T09:15:09.000Z - 7 weeks ago

Aligos Therapeutics presents data at EASL congress


Aligos Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Aligos Therapeutics Earnings release: Q1 2026


Aligos Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Aligos Therapeutics Quarterly report: Q1 2026


Aligos Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Proxy statement: Proxy filing


Aligos Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Proxy statement: Proxy filing


Aligos Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 3 months ago

Aligos Therapeutics Slides: Corporate presentation


Aligos Therapeutics initiated with a Buy at WestPark Capital

2026-03-26T13:00:14.000Z - 4 months ago

Aligos Therapeutics initiated with a Buy at WestPark Capital


Aligos Therapeutics Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Aligos Therapeutics Slides: Corporate presentation


Aligos Therapeutics assumed with a Buy at Jefferies

2026-03-19T09:15:20.000Z - 4 months ago

Aligos Therapeutics assumed with a Buy at Jefferies


Aligos Therapeutics Annual report: Q4 2025

Mar 5, 2026, 9:30 AM EST - 4 months ago

Aligos Therapeutics Annual report: Q4 2025


Aligos Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 9:30 AM EST - 4 months ago

Aligos Therapeutics Earnings release: Q4 2025


Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

2026-03-05T13:14:38.000Z - 4 months ago

Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)


Aligos Therapeutics appoints James Hassard as EVP, CCO

2026-01-13T13:16:17.000Z - 6 months ago

Aligos Therapeutics appoints James Hassard as EVP, CCO


Aligos Therapeutics initiated with a Buy at UBS

2026-01-07T13:21:19.000Z - 6 months ago

Aligos Therapeutics initiated with a Buy at UBS

APGE COGT IDYA IVA KOD SABS VTYX


Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Dec 11, 2025, 8:00 AM EST - 7 months ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025


Aligos Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Aligos Therapeutics Quarterly report: Q3 2025


Aligos Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Aligos Therapeutics Earnings release: Q3 2025


Aligos Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 AM EST - 9 months ago

Aligos Therapeutics to Present at Upcoming Investor Conferences


Aligos Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Aligos Therapeutics Quarterly report: Q2 2025


Aligos Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q2 2025


Aligos Therapeutics Quarterly report: Q1 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Quarterly report: Q1 2025


Aligos Therapeutics Earnings release: Q1 2025

May 6, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q1 2025


Aligos Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing


Aligos Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing


Aligos Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Proxy statement: Proxy Filing


Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at APASL 2025


Aligos Therapeutics Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Annual report: Q4 2024


Aligos Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Aligos Therapeutics Earnings release: Q4 2024


Aligos Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Quarterly report: Q3 2024


Aligos Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Aligos Therapeutics Earnings release: Q3 2024


Aligos Therapeutics Transcript: Study Result

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Transcript: Study Result


Aligos Therapeutics Press release: Study Result

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Press release: Study Result


Aligos Therapeutics Slides: Study Result

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Aligos Therapeutics Slides: Study Result


Aligos Therapeutics Announces Reverse Stock Split

Aug 15, 2024, 9:00 AM EDT - 2 years ago

Aligos Therapeutics Announces Reverse Stock Split


Aligos Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Quarterly report: Q2 2024


Aligos Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Aligos Therapeutics Earnings release: Q2 2024


ALGSmoon
ALGSmoon Jul. 15 at 5:58 PM
$ALGS I guess we see what it does at 5.50 trendnline.
1 · Reply
ALGSmoon
ALGSmoon Jul. 15 at 3:22 PM
$ALGS and just like that…the pumpers have left the building. The stock is giving back its gains, a new downtrend has begun and we’re right back to the same ole thing.
0 · Reply
biotrade123
biotrade123 Jul. 14 at 12:29 AM
$ALGS hmm.. why the AH big drop? ?
0 · Reply
ZRN227
ZRN227 Jul. 13 at 4:47 PM
$ALGS If anybody waiting for FDA approval they will wait long time. Chinese regulatory office is more efficient and faster. We might see the drug on their market even before the trials are done in USA. I believe the next customer will come from Asia also, but before that there will be a few insiders purchasing the stock at market price.
0 · Reply
JoButler
JoButler Jul. 13 at 3:00 PM
$ALGS just cleared an important development milestone. Enrollment is now complete for both Phase 2 B-SUPREME cohorts evaluating pevifoscorvir in chronic HBV, shifting the focus from recruitment to clinical readouts. The next major catalyst is topline safety and efficacy data expected in late Q3 2027. Until then, execution and data quality—not headlines—will likely drive the investment case.
2 · Reply
biotrade123
biotrade123 Jul. 13 at 2:41 PM
$ALGS pull back on low vol before it continues up??🤞🤞
0 · Reply
WillyT2
WillyT2 Jul. 11 at 4:06 PM
$ALGS Anyone who trades these low float tickers needs TapeGrid dot com, Profitable every week since using it. You can thank me later! $MIMI $ZBAO $JZXN
1 · Reply
Somedude632
Somedude632 Jul. 10 at 11:48 PM
0 · Reply
ZRN227
ZRN227 Jul. 10 at 8:03 PM
$ALGS This is an old news but so relevant for the future. There is still money left from the offering $26/share, and now they finally becoming profitable. https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-announces-105-million-private-placement
0 · Reply
Quantumup
Quantumup Jul. 10 at 6:14 PM
H.C. Wainwright (a/o 7/7) reit'd $ALGS Buy-$50 after hosting ALGS for a fireside chat. $GILD $ABUS ASMB GSK - IONS RHHBY VIR JNJ MDGL IVA VKTX LGND NVO Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2075644271281975530?s=20
0 · Reply
ajmrtxl
ajmrtxl Jul. 10 at 2:45 PM
$ALGS 's latest data on SqueezeFinder
0 · Reply
ZRN227
ZRN227 Jul. 10 at 1:05 PM
$ALGS I just realized $25 mil will not show on the Q2 earnings and that is maybe why the stock didn't fly yet. Anyway, it shouldn't matter much. The year will be 100%, for the first time profitable.
0 · Reply
Uncle_Tom
Uncle_Tom Jul. 10 at 5:50 AM
$ALGS only logical developement is an extensive MASH Deal for asset ALG-055009 , which is way better than Rezdiffra or VK2809 in side effects by same potency level. By the way , Lawrence Blatt is a deal maker, he knows the mind flow of Big Pharma and the potency of Aligos combo as „All in one“ package.
0 · Reply
Somedude632
Somedude632 Jul. 9 at 10:18 PM
1 · Reply
Investingclues
Investingclues Jul. 9 at 6:00 PM
$ALGS Absolutely being accumulated right now. Big news coming. Earnings in a month, should be quite impressive.
2 · Reply
Traderforlyf
Traderforlyf Jul. 9 at 4:47 PM
$ALGS trust me this will be 20 by end of this week. I have seen similar actions
2 · Reply
JCH007
JCH007 Jul. 9 at 3:01 PM
$ALGS I know the phrase, "It's being accumulated" gets thrown around a lot when stocks don't behave the way they should, but in this case, it is absolutely true. Guarantee, there are those with deep pockets, lining up their ducks, buying every dip, stacking up large quanties of shares. The impatient are giving up their shares for cheap, and that's what they are counting on. By suppressing the stock, they get to accumulate more and more shares at great prices.
1 · Reply
JCH007
JCH007 Jul. 9 at 2:26 PM
$ALGS I believe they screwed around with it long enough. Amount of volume is a joke. Needs to pop.
0 · Reply
Peak_Big
Peak_Big Jul. 9 at 2:02 PM
$ALGS sell pressure has slowed down a lot today creating less short volume which has cut most volume. Should see increased shareholder and market support as a result and push the price up. 🤞
0 · Reply
ZRN227
ZRN227 Jul. 9 at 1:03 PM
$ALGS Comparing financials Q2 with Q1 my math is this. Revenue minimum $25 mil/share, with expenses -$0.61/share, the earnings should be $3.35/share. Consensus estimate (Q2 2026) -$1.07. I guess we just to wait until Aug. 6th.
0 · Reply
Traderforlyf
Traderforlyf Jul. 9 at 7:24 AM
$ALGS why isn't there any action?
1 · Reply
JCH007
JCH007 Jul. 8 at 10:21 PM
$ALGS Price going up, but don't get excited. A whole 7 shares caused the price to go from 6.40 to 6.68. Market maker games.
1 · Reply